© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 11, 954-960,
June 2, 1999
© 1999 Oxford University Press
REPORTS |
Detection of Human Papillomavirus DNA in Cytologically Normal Women and Subsequent Cervical Squamous Intraepithelial Lesions
Affiliations of authors: K.-L. Liaw, S. Wacholder, M. Schiffman, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD; A. G. Glass, D. R. Scott, B. B. Rush, P. Lawler, Kaiser Permanente, Portland, OR; M. M. Manos, C. E. Greer, Cetus Corporation, Emeryville, CA; M. Sherman, R. J. Kurman, Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD; R. D. Burk, Albert Einstein College of Medicine, Bronx, NY; D. M. Cadell, D. Tabor, Westat Inc., Rockville, MD.
Correspondence to: Mark Schiffman, M.D., M.P.H., National Institutes of Health, Executive Plaza South, Rm. 7066, Bethesda, MD 20892.
BACKGROUND: Human papillomavirus (HPV) infection has been strongly associated with cervical carcinoma and its cytologic precursors, squamous intraepithelial lesions (SIL). We investigated the risk of SIL prospectively following polymerase chain reaction (PCR)-based DNA testing for a wide range of genital HPV types in a cohort of initially cytologically normal women, to clarify the role of HPV in the etiology of SIL. METHODS: Starting in April 1989, 17 654 women who were receiving routine cytologic screening at Kaiser Permanente (Portland, OR) were followed for the development of incident SIL. During follow-up, 380 incident case patients and 1037 matched control subjects were eligible for this nested case-control study. Cervical lavages collected at enrollment and, later, at the time of case diagnosis (or the corresponding time for selection of control subjects) were tested for HPV DNA using a PCR-based method. The data were analyzed as contingency tables with two-sided P values or, for multivariable analyses, using odds ratios (ORs) with 95% confidence intervals (CIs). RESULTS: In comparison with initially HPV-negative women, women who tested positive for HPV DNA at enrollment were 3.8 times (95% CI = 2.6-5.5) more likely to have low-grade SIL subsequently diagnosed for the first time during follow-up and 12.7 times more likely (95% CI = 6.2-25.9) to develop high-grade SIL. At the time of diagnosis, the cross-sectional association of HPV DNA and SIL was extremely strong (OR = 44.4 and 95% CI = 24.2-81.5 for low-grade SIL and OR = 67.1 and 95% CI = 19.3-233.7 for high-grade SIL). HPV16 was the virus type most predictive of SIL, even low-grade SIL. CONCLUSIONS: These findings are consistent with the hypothesis that HPV infection is the primary cause of cervical neoplasia. Furthermore, they support HPV vaccine research to prevent cervical cancer and efforts to develop HPV DNA diagnostic tests.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J.-F. Shi, J. L. Belinson, F.-H. Zhao, R. G. Pretorius, J. Li, J.-F. Ma, F. Chen, W. Xiang, Q.-J. Pan, X. Zhang, et al. Human Papillomavirus Testing for Cervical Cancer Screening: Results From a 6-Year Prospective Study in Rural China Am. J. Epidemiol., September 15, 2009; 170(6): 708 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Blatter and B. J. Monk The Pediatrician's Role in Preventing Cervical Cancer Clinical Pediatrics, September 1, 2008; 47(7): 627 - 638. [PDF]
|
|
|
|
|
|
J. Koshiol, L. Lindsay, J. M. Pimenta, C. Poole, D. Jenkins, and J. S. Smith Persistent Human Papillomavirus Infection and Cervical Neoplasia: A Systematic Review and Meta-Analysis Am. J. Epidemiol., July 15, 2008; 168(2): 123 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Koshiol, C. Poole, H. Chu, J. M. Pimenta, L. Lindsay, D. Jenkins, and J. S. Smith The Authors Respond to "HPV Persistence and Cervical Cancer Screening" Am. J. Epidemiol., July 15, 2008; 168(2): 145 - 148. [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Gravitt, M. Schiffman, D. Solomon, C. M. Wheeler, and P. E. Castle A Comparison of Linear Array and Hybrid Capture 2 for Detection of Carcinogenic Human Papillomavirus and Cervical Precancer in ASCUS-LSIL Triage Study Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1248 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Gravitt, L. J. van Doorn, W. Quint, M. Schiffman, A. Hildesheim, A. G. Glass, B. B. Rush, J. Hellman, M. E. Sherman, R. D. Burk, et al. Human Papillomavirus (HPV) Genotyping Using Paired Exfoliated Cervicovaginal Cells and Paraffin-Embedded Tissues To Highlight Difficulties in Attributing HPV Types to Specific Lesions J. Clin. Microbiol., October 1, 2007; 45(10): 3245 - 3250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kang and S. W. Lagakos Statistical methods for panel data from a semi-Markov process, with application to HPV Biostat., April 1, 2007; 8(2): 252 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Trottier, S. Mahmud, M. C. Costa, J. P. Sobrinho, E. Duarte-Franco, T. E. Rohan, A. Ferenczy, L. L. Villa, and E. L. Franco Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1274 - 1280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Burchell, H. Richardson, S. M. Mahmud, H. Trottier, P. P. Tellier, J. Hanley, F. Coutlee, and E. L. Franco Modeling the Sexual Transmissibility of Human Papillomavirus Infection using Stochastic Computer Simulation and Empirical Data from a Cohort Study of Young Women in Montreal, Canada Am. J. Epidemiol., March 15, 2006; 163(6): 534 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Khan, P. E. Castle, A. T. Lorincz, S. Wacholder, M. Sherman, D. R. Scott, B. B. Rush, A. G. Glass, and M. Schiffman The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical Practice J Natl Cancer Inst, July 20, 2005; 97(14): 1072 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Piyathilake, O. L. Henao, M. Macaluso, P. E. Cornwell, S. Meleth, D. C. Heimburger, and E. E. Partridge Folate Is Associated with the Natural History of High-Risk Human Papillomaviruses Cancer Res., December 1, 2004; 64(23): 8788 - 8793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Goldie, M. Kohli, D. Grima, M. C. Weinstein, T. C. Wright, F. X. Bosch, and E. Franco Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine J Natl Cancer Inst, April 21, 2004; 96(8): 604 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Syrjanen, I. Shabalova, N. Petrovichev, V. Kozachenko, T. Zakharova, J. Pajanidi, J. Podistov, G. Chemeris, L. Sozaeva, E. Lipova, et al. Acquisition of High-Risk Human Papillomavirus Infections and Pap Smear Abnormalities among Women in the New Independent States of the Former Soviet Union J. Clin. Microbiol., February 1, 2004; 42(2): 505 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Schlecht, R. W. Platt, A. Negassa, E. Duarte-Franco, T. E. Rohan, A. Ferenczy, L. L. Villa, and E. L. Franco Modeling the Time Dependence of the Association between Human Papillomavirus Infection and Cervical Cancer Precursor Lesions Am. J. Epidemiol., November 1, 2003; 158(9): 878 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Castle, A. T. Lorincz, D. R. Scott, M. E. Sherman, A. G. Glass, B. B. Rush, S. Wacholder, R. D. Burk, M. M. Manos, J. E. Schussler, et al. Comparison between Prototype Hybrid Capture 3 and Hybrid Capture 2 Human Papillomavirus DNA Assays for Detection of High-Grade Cervical Intraepithelial Neoplasia and Cancer J. Clin. Microbiol., September 1, 2003; 41(9): 4022 - 4030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Kulasingam and E. R. Myers Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs JAMA, August 13, 2003; 290(6): 781 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Strickler, J. M. Palefsky, K. V. Shah, K. Anastos, R. S. Klein, H. Minkoff, A. Duerr, L. S. Massad, D. D. Celentano, C. Hall, et al. Human Papillomavirus Type 16 and Immune Status in Human Immunodeficiency Virus-Seropositive Women J Natl Cancer Inst, July 16, 2003; 95(14): 1062 - 1071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Richardson, G. Kelsall, P. Tellier, H. Voyer, M. Abrahamowicz, A. Ferenczy, F. Coutlee, and E. L. Franco The Natural History of Type-specific Human Papillomavirus Infections in Female University Students Cancer Epidemiol. Biomarkers Prev., June 1, 2003; 12(6): 485 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Tachezy, M Salakova, E Hamsikova, J Kanka, A Havrankova, and V Vonka Prospective study on cervical neoplasia: presence of HPV DNA in cytological smears precedes the development of cervical neoplastic lesions Sex Transm Inf, June 1, 2003; 79(3): 191 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. X. Bosch and S. de Sanjose Chapter 1: Human Papillomavirus and Cervical Cancer--Burden and Assessment of Causality J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 3 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Schiffman and P. Castle Epidemiologic Studies of a Necessary Causal Risk Factor: Human Papillomavirus Infection and Cervical Neoplasia J Natl Cancer Inst, March 19, 2003; 95(6): E2 - E2. [Full Text]
|
|
|
|
|
|
M. E. Sherman, A. T. Lorincz, D. R. Scott, S. Wacholder, P. E. Castle, A. G. Glass, I. Mielzynska-Lohnas, B. B. Rush, and M. Schiffman Baseline Cytology, Human Papillomavirus Testing, and Risk for Cervical Neoplasia: A 10-Year Cohort Analysis J Natl Cancer Inst, January 1, 2003; 95(1): 46 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Mandelblatt, W. F. Lawrence, L. Gaffikin, K. K. Limpahayom, P. Lumbiganon, S. Warakamin, J. King, B. Yi, P. Ringers, and P. D. Blumenthal Costs and Benefits of Different Strategies to Screen for Cervical Cancer in Less-Developed Countries J Natl Cancer Inst, October 2, 2002; 94(19): 1469 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Castle, S. Wacholder, A. T. Lorincz, D. R. Scott, M. E. Sherman, A. G. Glass, B. B. Rush, J. E. Schussler, and M. Schiffman A Prospective Study of High-Grade Cervical Neoplasia Risk Among Human Papillomavirus-Infected Women J Natl Cancer Inst, September 18, 2002; 94(18): 1406 - 1414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K Kjaer, A. J C van den Brule, G. Paull, E. I Svare, M. E Sherman, B. L Thomsen, M. Suntum, J. E Bock, P. A Poll, and C. J L M Meijer Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study BMJ, September 14, 2002; 325(7364): 572 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Mandelblatt, W. F. Lawrence, S. M. Womack, D. Jacobson, B. Yi, Y.-t. Hwang, K. Gold, J. Barter, and K. Shah Benefits and Costs of Using HPV Testing to Screen for Cervical Cancer JAMA, May 8, 2002; 287(18): 2372 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. C. van den Brule, R. Pol, N. Fransen-Daalmeijer, L. M. Schouls, C. J. L. M. Meijer, and P. J. F. Snijders GP5+/6+ PCR followed by Reverse Line Blot Analysis Enables Rapid and High-Throughput Identification of Human Papillomavirus Genotypes J. Clin. Microbiol., March 1, 2002; 40(3): 779 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Castle, A. T. Lorincz, I. Mielzynska-Lohnas, D. R. Scott, A. G. Glass, M. E. Sherman, J. E. Schussler, and M. Schiffman Results of Human Papillomavirus DNA Testing with the Hybrid Capture 2 Assay Are Reproducible J. Clin. Microbiol., March 1, 2002; 40(3): 1088 - 1090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Schlecht, S. Kulaga, J. Robitaille, S. Ferreira, M. Santos, R. A. Miyamura, E. Duarte-Franco, T. E. Rohan, A. Ferenczy, L. L. Villa, et al. Persistent Human Papillomavirus Infection as a Predictor of Cervical Intraepithelial Neoplasia JAMA, December 26, 2001; 286(24): 3106 - 3114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Gravitt, J. V. Lacey Jr., L. A. Brinton, W. A. Barnes, J. R. Kornegay, M. D. Greenberg, S. M. Greene, O. C. Hadjimichael, L. McGowan, R. Mortel, et al. Evaluation of Self-Collected Cervicovaginal Cell Samples for Human Papillomavirus Testing by Polymerase Chain Reaction Cancer Epidemiol. Biomarkers Prev., February 1, 2001; 10(2): 95 - 100. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. F. Sawaya, D. Grady, K. Kerlikowske, J. L. Valleur, V. M. Barnabei, K. Bass, T. E. Snyder, J. H. Pickar, S. K. Agarwal, J. Mandelblatt, et al. The Positive Predictive Value of Cervical Smears in Previously Screened Postmenopausal Women: The Heart and Estrogen/progestin Replacement Study (HERS) Ann Intern Med, December 19, 2000; 133(12): 942 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Villa, L. Sichero, P. Rahal, O. Caballero, A. Ferenczy, T. Rohan, and E. L. Franco Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia J. Gen. Virol., December 1, 2000; 81(12): 2959 - 2968. [Abstract] [Full Text]
|
|
|
|
|
|
N. Ylitalo, A. Josefsson, M. Melbye, P. Sörensen, M. Frisch, P. K. Andersen, P. Sparén, M. Gustafsson, P. Magnusson, J. Pontén, et al. A Prospective Study Showing Long-Term Infection with Human Papillomavirus 16 before the Development of Cervical Carcinoma in Situ Cancer Res., November 1, 2000; 60(21): 6027 - 6032. [Abstract] [Full Text]
|
|
|
|
|
|
P. E. Gravitt, C. L. Peyton, T. Q. Alessi, C. M. Wheeler, F. Coutlée, A. Hildesheim, M. H. Schiffman, D. R. Scott, and R. J. Apple Improved Amplification of Genital Human Papillomaviruses J. Clin. Microbiol., January 1, 2000; 38(1): 357 - 361. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. D. Burk Pernicious Papillomavirus Infection N. Engl. J. Med., November 25, 1999; 341(22): 1687 - 1688. [Full Text]
|
|